New York – United States
Global Lymphedema Treatment Market is expected to gain significant growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the global lymphedema treatment market is growing with a CAGR of 9.2% in the forecast period of 2022 to 2029 and is expected to reach USD 1,671.51 million by 2029 from USD 841.00 million in 2022. Rising healthcare expenditure and escalation in innovation and technologies are major drivers which are expected to the growth of the market in the forecast period.
Lymphedema refers to swelling that generally occurs in upper and lower extremities. Sometimes both arms and both legs swell. Lymphedema is most commonly caused by the removal of or damage to lymph nodes as a part of cancer treatment. It results from a blockage in lymphatic system, which is part of immune system. Stems from a damaged lymphatic system, can lead to infections, disfigurement, debilitating pain and disability. There is no cure for lymphedema.
Also known as lymphatic obstruction, lymphedema can be a result of cancer or cancer treatment. Statistics have revealed that lymphedema may occur within days and up to 30 years after breast cancer treatment. As per a study, awareness, and early intervention are needed to reduce the impact of breast cancer-related lymphedema (2017). An estimated 10 million Americans suffer from lymphedema or related diseases. A retrospective analysis by Brayton and colleagues – who studied health claims data from a large national insurer – showed lymphedema prevalence among cancer survivors increased from 0.95% in 2007 to 1.24% in 2013.
Download the PDF Sample Report (Including FULL TOC, Graphs, and Tables) of Global Lymphedema Treatment Market report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-lymphedema-treatment-market&Shri
Increased prevalence of lymphedema is expected to drive the market’s growth rate
The high prevalence of the disease would lead to increased demand for lymphedema treatment, and thus there will be a surge in research and development for timely treatment of the patients, with funds being granted by public-private organizations and government organizations. It would also ensure the safe health of the patients. The aspect would deliver positive growth in the market.
Market Overview:
Lymphedema treatment involves multiple therapies instead of standard treatment, since the patients are dissatisfied or don’t get cured with the conventional treatment of lymphedema. They approach the alternative treatment which offers more control over health care decisions, and the alternatives are found to be more compatible with the patient’s health system.
Lymphedema can occur after any cancer or its treatment that affects lymph node drainage. It has been reported to occur within days and up to 30 years after treatment for breast cancer. The initial stage lymphedema treatments are therapies, surgeries and lymphovenous transplant among others. But there is no permanent cure for lymphedema.
A growing number of people are affected with by the lymphedema treatment which demand highly effective and advanced treatment to minimize the risk during the treatment. The healthcare systems need highly advanced treatment products. Therefore, the major market players are highly focusing on product launches and product approvals. Additionally, the government and regulatory bodies are supporting market players by virtue of product approval.
Major Players
Data Bridge Market Research recognizes the following companies as the major market players in market are medi Deutschland (Germany), PAUL HARTMANN AG (Germany), 3M (U.S.), Tactile Medical (U.S.), BIOCOMPRESSION SYSTEMS (U.S.), Lohmann & Rauscher GmbH & Co. KG (Germany), Mego Afek Ltd. (Israel), ThermoTek (U.S.), Cardinal Health (U.S.), Smith+Nephew (Germany), HERANTIS PHARMA Plc (Finland), Huntleigh Healthcare Limited (U.K.), Avet Pharmaceuticals Inc. (U.S.), and KOYA MEDICAL (U.S.).
Browse a Detailed Summary of Global Lymphedema Treatment Market Research Report @ https://www.databridgemarketresearch.com/reports/global-lymphedema-treatment-market?Shri
Segment Analysis:
- On the basis of treatment type, the global lymphedema treatment market is segmented into compression therapy, surgery, drug therapy, laser therapy and others. In 2022, compression therapy segment to dominate the global lymphedema treatment market with 66.88% market share as this effectively manages the disease symptoms.
- On the basis of type, the global lymphedema treatment market is segmented into secondary lymphedema and primary lymphedema. In 2022, secondary lymphedema segment is expected to dominate the global Lymphedema treatment market with 78.54% market share because secondary lymphedema is the most common lymphedema among the population.
- On the basis of affected area, the global lymphedema treatment market is segmented into lower extremity, upper extremity and genitalia. In 2022, lower extremity segment is expected to dominate the global lymphedema treatment market with 52.79% market share because lower extremities is found to be mostly affected in case of lymphedema.
- On the basis of age group, the global lymphedema treatment market is segmented into adult, geriatric and pediatric. In 2022, adult segment is expected to dominate the global lymphedema treatment market with 50.68% market share because relatively adults undergo surgeries and treatment which leads to lymphedema.
- On the basis of route of administration, the global lymphedema treatment market is segmented into oral, injectable and topical. In 2022, oral segment expected to dominate the global Lymphedema treatment market with 51.96% market share because it is most effective mode administration with better patient compliance.
- On the basis of end user, the global lymphedema treatment market is segmented into hospital, speciality clinics, ambulatory surgical centers and others. In 2022, hospitals segment is expected to dominate the global Lymphedema treatment market with 52.93% market share because of surging pool of lymphedema treatment patients.
The hospital will dominate the end user segment of the global lymphedema treatment market
- In 2022, the hospital segment is expected to flourish its dominance by acquiring more than 53% of the market share. This is because of the growth and expansion of the healthcare industry and growing demand for critical care by geriatric population base.
- On the basis of distribution channel, the global lymphedema treatment market is segmented into pharmacy stores, direct tender and others. In 2022, pharmacy stores segment is expected to dominate the global lymphedema treatment market with 52.39% market share owing to the rising among the target population and increasing R & D activities.
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Media Contact
Sopan Gedam
Organization: Data Bridge Market Research
Phone: +1-888-387-2818
Email: sales@databridgemarketresearch.com
Web: www.databridgemarketresearch.com